A private life science investment firm with a presence in USA, Canada, and Western Europe, looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $.5-$3million range. The firm is open to investing in companies located around the globe.
The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immunoncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.
The firm acts as hands-on investors who contribute substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Private Life Science Investment Firm Interested in Global Therapeutics Companies in Immuno-Oncology, Metabolic Disease, and More
19 AugHot Investor Mandate: Family Office with Over 30 Years of Experience Invests in Early-Stage Medtech & Digital Health Companies Based in North America and Europe
19 AugA family office founded over 30 years ago has recently been restarted, and has recently transitioned to have a stronger healthcare focus after coming out of dormancy and is seeking to make equity investments in the $200K – $2M USD range. The firm is a multi-stage longer term oriented investor interested in new and more seasoned emerging growth companies addressing a broad range of Healthcare and Medical products and services opportunities. The firm invests in companies based in North America and Europe and is actively seeking new investment opportunities.
The firm is interested in Medtech and Healthcare IT projects that are transformative and disruptive within their fields. The firm is not interested in therapeutics, vaccines, molecules, or any healthcare projects with undefined regulatory approval cycles. Otherwise, the firm is rather opportunistic within the Medtech and Healthcare IT sectors.
When investing, the firm seeks a board seat and prefers to get involved with the management team. As a result, the firm prefers a management team that is willing to work with them together as partners.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Cross-Border VC Invests Up to $16M in Global Therapeutics Companies, Open to All Types of Modalities and Indications
19 AugA cross-border venture capital firm headquartered in Asia with USA offices, with a recently launched incubator business, typically makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide.
The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.
The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Asia-Based Firm With Large Hospital Network Invests in Digital Health Companies Seeking to Expand into Asian Markets
19 AugA firm that operates a large hospital network across Asia and the Middle East has an innovation office that acts as a corporate VC arm, which has committed capital of $80 million to invest in the digital health space. The firm typically invests $5-10 million per opportunity, and will invest in companies worldwide that are interested in expanding into Asia.
The firm only invests in the digital health space. The firm is interested in many areas of digital health, diagnostics, and tech-enabled healthcare services, including wellness, digital therapeutics, AI, healthcare data, remote monitoring, chronic disease management, etc. The firm does not invest in biopharma or medtech.
The firm will invest globally, and is focused on startups that are interested in expanding into Asia.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Automating Medical Visits Using Artificial Intelligence (AI) and Augmented Reality (AR) – Interview with James Bates, MS, CEO of AdviNOW Medical
16 AugBy Erika Wu, Business Development Representative, LSN
What if we could automate and improve medical visits by reducing in-person patient contact, administrative burdens and operation costs? Hear what CEO James Bates and his team at AdviNOW Medical are doing to utilize AR and AI to expand healthcare access to anywhere you are. RESI AI returns September 16-17 with dynamic panels, as well as opportunities to pitch to a live panel of AI investors. Get involved and tell your story at Innovator’s Pitch Challenge! Applications are due by Friday, August 20, so submit yours today!
September Partnering Opens Soon
12 AugBy Karen Deyo, Director of Investor Research, Israel BD, LSN
Life Science Nation (LSN)’s mission is to connect products, services, and capital to advance deals that save lives. There are many opportunities to achieve this in the early-stage life science ecosystem, but few more powerful than well-matched partnering, which is why LSN’s match-based partnering platform can be a game-changer for fundraising entrepreneurs.
Learn more about virtual partnering at LSN events at one of our free fundraising bootcamps coming up on Wednesday, August 18 at 2 PM EDT. Register here for the complimentary webinar. These events give an overview of LSN’s partnering system, what sets it apart, and why a comprehensive strategy is essential to succeed in booking meetings with qualified investors.
Check out some of our resources below to help you succeed in your partnering, and sign up for our one-day prep course ahead of RESI Partnering Week, September 13-17 to get started!
- Global Roadshow Prep Course + RESI Partnering Week Bundle
- Partnering Strategies for Success
- Outreach and Marketing Collateral
- Pitching Like a Pro
- Follow Up, Follow Up, Follow Up!
Pitch Deadline Approaching
12 AugBy Rory McCann, Marketing Manager & Conference Producer, LSN
The application deadline to pitch at RESI Partnering Week, September 13-17 is around the corner. Submit your application to pitch directly to a panel of relevant investors by August 20. Applications are accepted on a rolling basis.
The Innovator’s Pitch Challenge (IPC) provides an opportunity for life science startups to pitch directly to a panel of investors during a live Q&A session, providing valuable insights and feedback. Participants build connections between fundraising founders and potential investors on the panel and in the audience.
Participating companies receive:
- A dedicated page showcasing a pre-recorded pitch video, pitch deck, and executive summary
- A spot in the live pitch session and Q&A with investors actively seeking assets in their sector
- Global visibility to partners that are a fit for their stage of development and product
- Increased global footprint, opportunities to engage with global partners, and valuable, insightful feedback
Hear from recent IPC winners, see what investors have to say, and sign up today to pitch at RESI Partnering Week!
See What Investors Are Saying about The Innovator’s Pitch Challenge
 “It was a very economical use of time; the investors got to ask their important questions and the Innovators got a good idea of the most pressing questions from the investors point of view.”William Kuziel, MedPro Investors
 “The Pitch Sessions are a great opportunity to connect with startup CEOs and learn more about their work…It really has been an effective and efficient way to make connections, create deal flow and help startups raise money for their upcoming raises.”Mayank Taneja, OSF Healthcare
 “I look forward to LSN’s events because they provide an opportunity for our venture capital firm to find promising companies with exceptional technologies. The organization and technology platform make it very easy to hear numerous pitches from founders.”Nat Brinn, VC23
 “The Pitch Sessions were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.”Gary Gershony, Life Science Angels / BayMed Venture Partners
|
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 